The impact of the FDA Safety and Innovation Act (FDASIA) on the Center for Drug Evaluation and Research (CDER) is beginning to be felt as the center comes to grips with implementing the requirements of the Act and the organizational effort it will take to meet them.
At the Food and Drug Law Institute (FDLI) annual meeting in late April in Washington, D.C., FDA Commissioner Margaret Hamburg characterized FDASIA as “a wide-ranging statute that strikes many important themes and affects numerous public health issues on FDA’s agenda.”
In addressing the meeting, CDER Director Janet Woodcock commented that over a five-year period, FDASIA places 150 specific requirements on the agency, including the promulgation of 19 regulations and 24 guidances, and 14 reports to Congress.
In passing FDASIA, Congress granted FDA important new authorities, reauthorized human drug and medical device user fees, and authorized new user fees for generic drugs and biosimilars (IPQ “The News in Depth” February 13, 2012 and September 12, 2012).
Specifically, Title VII gives FDA additional tools it has been seeking to better confront the challenges of regulating a global supply chain (IPQ “The News in Depth” October 9, 2012). Provisions in the catch-all Title XI include a new system for the registration of medical gases and FDA participation in standard setting for nanotechnology particle-containing products that will further the Act’s impact on CMC and GMP regulatory processes (IPQ “The News in Depth” October 8, 2012).
[CLICK HERE for the complete story.and includes Woodcock’s review of the quality initiatives that CDER is undertaking in the wake of FDASIA. Nonsubscribers can purchase the story for $195 by contacting Jonathan Trethowan (Jonathan@ipq.org). For subscription/license information, click here.]
See related IPQ stories: